Movatterモバイル変換


[0]ホーム

URL:


Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Nature Publishing Group full text link Nature Publishing Group
Full text links

Actions

.2004 Sep 30;431(7008):525-6.
doi: 10.1038/431525b.

Lung cancer: intragenic ERBB2 kinase mutations in tumours

Philip Stephens  1Chris HunterGraham BignellSarah EdkinsHelen DaviesJon TeagueClaire StevensSarah O'MearaRaffaella SmithAdrian ParkerAndy BarthorpeMatthew BlowLisa BrackenburyAdam ButlerOliver ClarkeJennifer ColeEd DicksAngus DikeAnja DrozdKen EdwardsSimon ForbesRebecca FosterKristian GrayChris GreenmanKelly HallidayKaty HillsVivienne KosmidouRichard LuggAndy MenziesJanet PerryRobert PettyKeiran RaineLewis RatfordRebecca ShepherdAlexandra SmallYvonne StephensCalli ToftsJennifer VarianSofie WestSara WidaaAndrew YatesFrancis BrasseurColin S CooperAdrienne M FlanaganMargaret KnowlesSuet Y LeungDavid N LouisLeendert H J LooijengaBruce MalkowiczMarco A PierottiBin TehGeorgia Chenevix-TrenchBarbara L WeberSiu T YuenGrace HarrisPeter GoldstrawAndrew G NicholsonP Andrew FutrealRichard WoosterMichael R Stratton
Affiliations

Lung cancer: intragenic ERBB2 kinase mutations in tumours

Philip Stephens et al. Nature..

Abstract

The protein-kinase family is the most frequently mutated gene family found in human cancer and faulty kinase enzymes are being investigated as promising targets for the design of antitumour therapies. We have sequenced the gene encoding the transmembrane protein tyrosine kinase ERBB2 (also known as HER2 or Neu) from 120 primary lung tumours and identified 4% that have mutations within the kinase domain; in the adenocarcinoma subtype of lung cancer, 10% of cases had mutations. ERBB2 inhibitors, which have so far proved to be ineffective in treating lung cancer, should now be clinically re-evaluated in the specific subset of patients with lung cancer whose tumours carry ERBB2 mutations.

PubMed Disclaimer

MeSH terms

Substances

LinkOut - more resources

Full text links
Nature Publishing Group full text link Nature Publishing Group
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.


[8]ページ先頭

©2009-2026 Movatter.jp